GEN Exclusives

More »

GEN News Highlights

More »
May 1, 2012

More than Half of GEN Poll Respondents Side With President Obama Over Ryan on Budget Size

  • By a more than 2-to-1 margin, GEN readers favor President Barack Obama’s budget proposal over that of the chairman of the House of Representatives Committee on the Budget, Rep. Paul Ryan (R-WI), and fellow House Republicans. More than half (57.6%) of respondents side with the president compared with over a quarter of respondents (25.8%) who side instead with Ryan. Another 15.2% support neither Obama nor Ryan, while 1.5% were undecided.

    Congressional squabbling over the federal budget for the 2013 fiscal year goes beyond the usual details of agency-by-agency spending to the overlaying question of how large the overall budget should be. On March 29, Ryan got his plan passed in the Republican-controlled House on a mostly party-line vote of 228–191. HCR 112 incorporates “Path to Prosperity,” introduced last year, which calls for overall spending of $3.53 trillion, including $1.028 trillion in nondefense discretionary spending. The nondefense discretionary spending cap is $19 billion below the $1.047 trillion level set under the Budget Control Act (BCA). The GOP budget blueprint envisions a $797 billion shortfall based on revenues of $2.734 trillion. President Obama’s $3.717 trillion budget proposal for FY 2013 includes a $977 billion deficit on $2.741 trillion in revenue.

     


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?